2-Hydroxyoleate, anontoxic membrane binding anticancer drug, induces glioma cell differentiation and autophagy

Proceedings of the National Academy of Sciences of the United States of America

Volumn 109, Issue 22, 2012, Pages 8489-8494

  Terés, Silvia ^a   Lladó, Victoria ^a   Higuera, Mónica ^a   Barceló Coblijn, Gwendolyn ^a   Martin, Maria Laura ^a   Noguera Salvà, Maria Antònia ^a   Marcilla Etxenike, Amaia ^a   García Verdugo, José Manuel ^b   Soriano Navarro, Mario ^b   Saus, Carlos ^a   Gómez Pinedo, Ulises ^c   Busquets, Xavier ^a   Escribá, Pablo V ^a  

^a UNIVERSITAT DE LES ILLES BALEARS   (Spain)

^b CENTRO DE INVESTIGACIÓN PRÍNCIPE FELIPE   (Spain)

^c HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

Cancer drug target; Fatty acids; Glioma biomarker; Sphingomyelin synthase

Indexed keywords

2 HYDROXYOLEIC ACID; ANTINEOPLASTIC AGENT; CYCLIN D; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; MEMBRANE LIPID; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; RAS PROTEIN; RETINOBLASTOMA PROTEIN; SPHINGOMYELIN; TEMOZOLOMIDE; UNCLASSIFIED DRUG; 2-HYDROXYOLEIC ACID; DACARBAZINE; DRUG DERIVATIVE; OLEIC ACID; PHOSPHATIDYLINOSITOL 3 KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOPHAGY; CELL DEATH; CELL DIFFERENTIATION; CONTROLLED STUDY; CYTOPLASM; DOWN REGULATION; DRUG EFFICACY; GLIA CELL; GLIOMA; GLIOMA CELL; HUMAN; HUMAN CELL; LIPID COMPOSITION; MEMBRANE BINDING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; RELAPSE; SIGNAL TRANSDUCTION; ANIMAL; CELL MEMBRANE; CELL PROLIFERATION; CELL SURVIVAL; CHEMISTRY; CONFOCAL MICROSCOPY; DOSE RESPONSE; DRUG EFFECT; DRUG SCREENING; MALE; METABOLISM; NUDE MOUSE; PATHOLOGY; PROTEIN TRANSPORT; TIME; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; AUTOPHAGY; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL MEMBRANE; CELL PROLIFERATION; CELL SURVIVAL; DACARBAZINE; DOSE-RESPONSE RELATIONSHIP, DRUG; GLIOMA; HUMANS; MALE; MAP KINASE SIGNALING SYSTEM; MEMBRANE LIPIDS; MICE; MICE, NUDE; MICROSCOPY, CONFOCAL; OLEIC ACIDS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN TRANSPORT; PROTO-ONCOGENE PROTEINS C-AKT; RAS PROTEINS; TIME FACTORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84861914891     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1118349109     Document Type: Article

References (42)

1. Brenner H, et al. (2009) Long-term survival expectations of cancer patients in Europe in 2000-2002. Eur J Cancer 45:1028-1041.
2. Louis DN (2006) Molecular pathology of malignant gliomas. Annu Rev Pathol 1:97-117.
3. Stupp R, et al. (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. New Engl J Med 352:987-996. (Pubitemid 40349501)
4. Martínez J, et al. (2005) Membrane structure modulation, protein kinase Cα activation, and anticancer activity of Minerval. Mol Pharmacol 67:531-540. (Pubitemid 40216746)
5. Martínez J, et al. (2005) The repression of E2F-1 is critical for the activity of Minerval against cancer. J Pharmacol Exp Ther 315:466-474. (Pubitemid 41380543)
6. Lladó V, et al. (2009) Pivotal role of dihydrofolate reductase knockdown in the anticancer activity of 2-hydroxyoleic acid. Proc Natl Acad Sci USA 106:13754-13758.
7. Yung WK, et al. (1999) Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse Temodal Brain Tumor Group. J Clin Oncol 17:2762-2771. (Pubitemid 29415233)
8. Omar AI, Mason WP (1999) Temozolomide: The evidence for its therapeutic efficacy in malignant astrocytomas. Core Evid 4:93-111.
9. Barceló F, et al. (2004) The hypotensive drug 2-hydroxyoleic acid modifies the structural properties of model membranes. Mol Membr Biol 21:261-268. (Pubitemid 39208301)
10. Goñi FM, Alonso A (1999) Structure and functional properties of diacylglycerols in membranes. Prog Lipid Res 38:1-48. (Pubitemid 29090112)
11. Harrisingh MC, Lloyd AC (2004) Ras/Raf/ERK signaling and NF1. Cell Cycle 3:1255-1258.
12. Katz M, Amit I, Yarden Y (2007) Regulation of MAPKs by growth factors and receptor tyrosine kinases. Biochim Biophys Acta 1773:1161-1176. (Pubitemid 47125978)
13. Griffero F, et al. (2009) Different response of human glioma tumor-initiating cells to epidermal growth factor receptor kinase inhibitors. J Biol Chem 284:7138-7148.
14. Wong ML, Kaye AH, Hovens CM (2007) Targeting malignant glioma survival signalling to improve clinical outcomes. J Clin Neurosci 14:301-308. (Pubitemid 46335778)
15. Kolch W (2000) Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions. Biochem J 351:289-305.
16. Leicht DT, et al. (2007) Raf kinases: function, regulation and role in human cancer. Biochim Biophys Acta 1773:1196-1212. (Pubitemid 47161035)
17. Parsa AT, Holland EC (2004) Cooperative translational control of gene expression by Ras and Akt in cancer. Trends Mol Med 10:607-613. (Pubitemid 39573152)
18. Tatevossian RG, et al. (2010) MAPK pathway activation and the origins of pediatric low-grade astrocytomas. J Cell Physiol 222:509-514.
19. Gwak J, et al. (2006) Protein-kinase-C-mediated beta-catenin phosphorylation negatively regulates the Wnt/beta-catenin pathway. J Cell Sci 119:4702-4709. (Pubitemid 44964266)
20. Gwak J, et al. (2009) Stimulation of protein kinase C-α suppresses colon cancer cell proliferation by down-regulation of beta-catenin. J Cell Mol Med 13:2171-2180.
21. Gartel AL, Tyner AL (2002) The role of the cyclin-dependent kinase inhibitor p21 in apoptosis. Mol Cancer Ther 1:639-649.
22. Marushige Y, et al. (1987) Modulation of growth and of morphological characteristics in glioma cells by nerve growth factor and glia maturation factor. Cancer Res 47:4109-4115. (Pubitemid 17108479)
23. Lee K, et al. (2005) Downregulation of GFAP, TSP-1, and p53 in human glioblastoma cell line, U373MG, by IE1 protein from human cytomegalovirus. Glia 51:1-12. (Pubitemid 41059153)
24. Leszczyniecka M, Roberts T, Dent P, Grant S, Fisher PB (2001) Differentiation therapy of human cancer: basic science and clinical applications. Pharmacol Ther 90:105-156. (Pubitemid 32926714)
25. Escribá PV (2006) Membrane-lipid therapy: a new approach in molecular medicine. Trends Mol Med 12:34-43.
26. Barceló-Coblijn G, et al. (2011) Sphingomyelin and sphingomyelin synthase (SMS) in the malignant transformation of glioma cells and in 2-hydroxyoleic acid therapy. Proc Natl Acad Sci USA 108:19569-19574.
27. Widemann BC, et al. (2011) Phase 1 trial and pharmacokinetic study of the farnesyl transferase inhibitor tipifarnib in children and adolescents with refractory leukemias: a report from the Children's Oncology Group. Pediatr Blood Cancer 56:226-233.
28. Mollinedo F, et al. (2010) Lipid raft-targeted therapy in multiple myeloma. Oncogene 29:3748-3757.
29. Modrak DE, Leon E, Goldenberg DM, Gold DV (2009) Ceramide regulates gemcitabine-induced senescence and apoptosis in human pancreatic cancer cell lines. Mol Cancer Res 7:890-896.
30. Escribá PV, et al. (1997) Role of lipid polymorphism in G protein-membrane interactions: nonlamellar-prone phospholipids and peripheral protein binding to membranes. Proc Natl Acad Sci USA 94:11375-11380. (Pubitemid 27451006)
31. Vögler O, et al. (2004) The Gβγ dimer drives the interaction of heterotrimeric Gi proteins with nonlamellar membrane structures. J Biol Chem 279:36540-36545. (Pubitemid 39128996)
32. Barceló F, et al. (2007) Interaction of the C-terminal region of the Ggamma protein with model membranes. Biophys J 93:2530-2541. (Pubitemid 47511152)
33. Guha A, Feldkamp MM, Lau N, Boss G, Pawson A (1997) Proliferation of human malignant astrocytomas is dependent on Ras activation. Oncogene 15:2755-2765. (Pubitemid 28004565)
34. Ohgaki H, Kleihues P (2009) Genetic alterations and signaling pathways in the evolution of gliomas. Cancer Sci 100:2235-2241.
35. Omerovic J, Laude AJ, Prior IA (2007) Ras proteins: paradigms for compartmentalised and isoform-specific signalling. Cell Mol Life Sci 64:2575-2589. (Pubitemid 350035604)
36. Holland EC (2000) A mouse model for glioma: biology, pathology, and therapeutic opportunities. Toxicol Pathol 28:171-177.
37. Kip1 expression in a mouse model of Kras-driven lung cancer. Oncogene 28:3652-3662.
38. Irvine RF (2003) Nuclear lipid signalling. Nat Rev Mol Cell Biol 4:1-12.
39. Lefranc F, Facchini V, Kiss R (2007) Proautophagic drugs: a novel means to combat apoptosis-resistant cancers, with a special emphasis on glioblastomas. Oncologist 12:1395-1403.
40. Ferraro E, Cecconi F (2007) Autophagic and apoptotic response to stress signals in mammalian cells. Arch Biochem Biophys 462:210-219. (Pubitemid 46856320)
41. Jiang H, et al. (2010) The RB-E2F1 pathway regulates autophagy. Cancer Res 70:7882-7893.
42. Dalby KN, et al. (2010) Targeting the prodeath and prosurvival functions of autophagy as novel therapeutic strategies in cancer. Autophagy 6:322-329.